---
title: "12 Health Care Stocks Moving In Tuesday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305069713.md"
description: "During Tuesday's after-market session, several healthcare stocks experienced significant volatility. Gainers included Basel Medical Group (up 13.9%), Longeveron (up 5.3%), and Instinct Bio Technical (up 4.55%). Conversely, losers featured Stereotaxis (down 16.1%), Karyopharm Therapeutics (down 10.92%), and Neuronetics (down 9.96%). Notably, Q3 earnings reports were released for companies such as MaxCyte, NovoCure, and Stereotaxis, influencing their respective stock movements."
datetime: "2026-11-10T21:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305069713.md)
  - [en](https://longbridge.com/en/news/305069713.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305069713.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Tuesday's After-Market Session

### Gainers

-   **Basel Medical Group** (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million.
-   **Longeveron** (NASDAQ:LGVN) stock moved upwards by 5.3% to $2.99. The market value of their outstanding shares is at $6.4 million.
-   **Instinct Bio Technical Co** (NASDAQ:BIOT) shares increased by 4.55% to $0.18. The company's market cap stands at $5.3 million.
-   **Firefly Neuroscience** (NASDAQ:AIFF) stock rose 4.46% to $1.02. The company's market cap stands at $14.8 million.
-   **MaxCyte** (NASDAQ:MXCT) shares moved upwards by 4.42% to $1.18. The market value of their outstanding shares is at $134.1 million. The company's, Q3 earnings came out today.
-   **NovoCure** (NASDAQ:NVCR) shares increased by 4.06% to $12.29. The market value of their outstanding shares is at $1.4 billion.

### Losers

-   **Stereotaxis** (AMEX:STXS) stock fell 16.1% to $0.88 during Tuesday's after-market session. The company's market cap stands at $114.2 million. The company's, Q3 earnings came out today.
-   **Karyopharm Therapeutics** (NASDAQ:KPTI) shares fell 10.92% to $0.02.
-   **Neuronetics** (NASDAQ:STIM) stock decreased by 9.96% to $1.81. The market value of their outstanding shares is at $166.1 million. As per the news, the Q3 earnings report came out 4 days ago.
-   **Exicure** (NASDAQ:XCUR) stock declined by 8.22% to $0.99. The company's market cap stands at $5.8 million.
-   **Mustang Bio** (NASDAQ:MBIO) shares declined by 4.69% to $0.43. The market value of their outstanding shares is at $2.9 million.
-   **Skye Bioscience** (NASDAQ:SKYE) stock fell 4.65% to $0.8. The market value of their outstanding shares is at $3.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [BIOT.US](https://longbridge.com/en/quote/BIOT.US.md)
- [BMGL.US](https://longbridge.com/en/quote/BMGL.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [LGVN.US](https://longbridge.com/en/quote/LGVN.US.md)
- [STIM.US](https://longbridge.com/en/quote/STIM.US.md)
- [STXS.US](https://longbridge.com/en/quote/STXS.US.md)
- [KPTIQ.US](https://longbridge.com/en/quote/KPTIQ.US.md)
- [AIFF.US](https://longbridge.com/en/quote/AIFF.US.md)
- [MBIO.US](https://longbridge.com/en/quote/MBIO.US.md)
- [MXCT.US](https://longbridge.com/en/quote/MXCT.US.md)
- [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md)
- [SKYE.US](https://longbridge.com/en/quote/SKYE.US.md)
- [XCUR.US](https://longbridge.com/en/quote/XCUR.US.md)

## Related News & Research

- [BUZZ-Neuronetics falls after starting share offering](https://longbridge.com/en/news/305067088.md)
- [Neuronetics (STIM) Prices $30M Offering; Proceeds May Address Going Concern Risk](https://longbridge.com/en/news/305106360.md)
- [Stereotaxis Announces Up to $24 Million Convertible Note Financing](https://longbridge.com/en/news/305064883.md)
- [Stereotaxis Q3 net loss widens to $6.48 million year over year; Q3 revenue rises 20% to $8.9 million year over year](https://longbridge.com/en/news/305065072.md)
- [Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial](https://longbridge.com/en/news/304290863.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**